Delving into the Latest Updates on HERV Targeted TCR-T(Immunoscape) with Synapse

Overview

Basic Info

Drug Type

TCR therapy

Synonyms-

Target

Human endogenous retroviral elements

Mechanism

Human endogenous retroviral elements inhibitors

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

ImmunoSCAPE Pte Ltd.Startup

Active Organization

ImmunoSCAPE Pte Ltd.Startup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Endogenous retroviral sequences provide a molecular fossil record of ancient infections whose analysis might illuminate mechanisms of viral extinction. A close relative of gammaretroviruses, HERV-T, circulated in primates for ~25 million years (MY) before apparent extinction within the past ~8 MY. Construction of a near-complete catalog of HERV-T fossils in primate genomes allowed us to estimate a ~32 MY old ancestral sequence and reconstruct a functional envelope protein (ancHTenv) that could support infection of a pseudotyped modern gammaretrovirus. Using ancHTenv, we identify monocarboxylate transporter-1 (MCT-1) as a receptor used by HERV-T for attachment and infection. A single HERV-T provirus in hominid genomes includes an env gene (hsaHTenv) that has been uniquely preserved. This apparently exapted HERV-T env could not support virion infection but could block ancHTenv mediated infection, by causing MCT-1 depletion from cell surfaces. Thus, hsaHTenv may have contributed to HERV-T extinction, and could also potentially regulate cellular metabolism.

100 Deals associated with HERV Targeted TCR-T(Immunoscape)

Login to view more data